Skip to main content
OpenTrials
Completed

NCT Number: NCT05830162

Oral Antibiotics After Obstetric Perineal Tear

The purpose of this study is to investigate if 3 dose of oral antibiotics administrated the first day after a vaginal delivery with a second degree obstetric tear will decrease the risk of infection and/or wound dehiscence compared to women with 3 doses of placebo treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Maternaty ward, Herlev Hospital

Herlev, 2730, Denmark

About this study

Background:

Obstetric tear occurs in more than 90% of nulliparous women and up to 25% subsequently experience wound dehiscence and/or infection. Some data shows that intravenous antibiotics given during delivery reduces this risk. It is unknown if oral antibiotics given after delivery can reduce the risk of wound dehiscence or infection.

The study-goupe want to investigate whether three doses of antibiotics (amoxicillin 500 mg / clavulanic acid 125 mg) given after delivery can reduce the risk of wound dehiscence and infection.

Methods:

The investigators will perform a randomized, controlled, double-blinded study and plan to include 221 women in each arm with allocation 1:1 in relation to the randomization. The study is carried out at Department of Obstetrics & Gynecology, Herlev University Hospital, Copenhagen, Denmark. The women will be included after delivery if they have had a second-degree tear or episiotomy. The first tabelt has to be taken with in 6 hours from the delivery. After inclusion, the women will have a clinical follow up visit after one week. The tear and healing will be evaluated regarding infection and/or dehiscence. The women will again be invited for a one year clinical examination including ultrasound. Questionaries exploring symptoms related to the vaginal tear and possible complications will be answered at both visits.

The primary outcome is wound dehiscence and/or wound infection, which will be calculated using χ2-tests to compare groups. Secondary outcomes are variables that relate to wound healing, for example pain, use of painkillers, need for further follow-up, as well as other outcomes that may be related to the birth or healing process; urinary or anal incontinence, symptoms of prolapse, female body image and sexual problems.

Discussion:

Reducing the risk of wound dehiscence and/or infection would decrease the number of control visits, prevent the need for longer antibiotic treatment and possibly also decrease both short-term and long-term symptoms. This would be of great importance since the period after a delivery is a crucial time for the whole family.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Danish speaking women above 18 years
  • Second degree perineal tear and/or episiotomy
  • Suturing of obstetric tear at Herlev Hospital

Exclusion criteria

  • Allergies to the treatment.
  • Women who end up with a cesarean-section, including those who have obstetric tears that require stitching or have had an episiotomy
  • Women who receive antibiotics intra- or postpartum for other reasons.

Treatment and study plan

Placebo

Drug

We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy

Bioclavid (Amoxicillin and Clavulanic acid)

Drug

We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy

Primary outcomes

  1. Infection in the obstetric tear

    Time frame: Infection will be evaluated 1-2 weeks after the delivery.

    We used the REEDA criteria-Redness, Edema, Ecchymosis, Discharge, and Approximation-to assess this outcome. However, we only diagnosed infection in cases where there was clear clinical evidence, in this study defined as the presence of an abscess or significant wound discharge. In instances of pronounced redness, edema, ecchymosis, or smaller amounts of discharge, these findings were recorded as possible infection or possible resolved infection in the patient's notes as observational comment.

  2. Wound dehiscence

    Time frame: Wound dehiscence will be evaluated 1-2 weeks after the delivery

    We will measure the amount of dehiscence and if above 5 mm it will be diagnoses as a wound dehiscence.

Secondary outcomes

  1. Clinically Relevant Wound Dehiscence

    Time frame: 1-2 weeks post partum

    Throughout the study, we noted a high incidence of wound dehiscence, characterized by a separation of wound edges (diastasis) greater than 5 mm. While some cases were minor, superficial, and without signs of infection, others were more severe. To better assess these more significant cases, we introduced a new secondary outcome: clinically relevant wound dehiscence. This classification was applied to wounds for which the clinician assessed that further follow-up was necessary based on the extent of the dehiscence, the severity of pain, or signs of infection

  2. Pain

    Time frame: 9-12 months after delivery.

    Questionnaire with use of Visual Analogue Scale (VAS) from 1-10 with 10 being the worst pain.

  3. Sexual problems

    Time frame: 9-12 months after delivery.

    Questionnaire

  4. Body image

    Time frame: 9-12 months after delivery.

    Questionnaire -

  5. Number of patients with prolapse

    Time frame: 9-12 months after delivery.

    Gynaecological examination

  6. Prolapse

    Time frame: 9-12 months after delivery.

    Questionnaire (asking if the women have had symptoms of prolapse)

  7. incontinence

    Time frame: 9-12 months after delivery.

    Questionnaire

Sponsors and collaborators

Lead sponsor

Hanna Jangö

Other

Collaborators

  • Region Hovedstadens Apotek

Registry information

Official study title

Oral Antibiotics to Prevent Infection and Wound Dehiscence After Obstetric Perineal Tear - a Double-blinded Placebo Controlled Randomized Trail

Acronym: REPAIR

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 26, 2023
Registry last updated
Dec 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.